Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26161298
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26161298
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Chemotherapy+(Los+Angel)
2014 ; 3
(3
): ä Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Antimetabolite Treatment for Pancreatic Cancer
#MMPMID26161298
Valenzuela MM
; Neidigh JW
; Wall NR
Chemotherapy (Los Angel)
2014[Dec]; 3
(3
): ä PMID26161298
show ga
Pancreatic cancer is a deadly and aggressive disease. Less than 1% of diagnosed
patients survive 5 years with an average survival time of only 4-8 months. The
only option for metastatic pancreatic cancer is chemotherapy where only the
antimetabolites gemcitabine and 5-fluorouracil are used clinically.
Unfortunately, efforts to improve chemotherapy regimens by combining,
5-fluorouracil or gemcitabine with other drugs, such as cisplatin or oxaliplatin,
have not increased cell killing or improved patient survival. The novel
antimetabolite zebularine shows promise, inducing apoptosis and arresting
cellular growth in various pancreatic cancer cell lines. However, resistance to
these antimetabolites remains a problem highlighting the need to discover and
develop new antimetabolites that will improve a patient's overall survival.